Kamada Ltd. (KMDA) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents mixed signals: while there's a positive revenue growth outlook for 2026 and dividend declaration, current financials show a gross margin decline and economic uncertainties. The Q&A session didn't reveal any major concerns, but competitive pressures and regulatory delays pose risks. Without a market cap, assuming moderate impact, the overall sentiment remains neutral, balancing positive long-term guidance against short-term challenges.
Key Financial Performance
Total Revenues $42.5 million in Q1 2026, a 3% increase from $44 million in Q1 2025. The increase was primarily driven by increased sales of KEDRAB and increased sales in the distribution segment.
Gross Profit and Gross Margins $19.1 million and 42% in Q1 2026 compared to $20.7 million and 47% in Q1 2025. The reduction in gross margin was affected by products and market sales mix.
Operating Expenses $12.1 million in Q1 2026 compared to $13 million in Q1 2025. The decrease was driven by a reduction in R&D expenses related to the termination of the Phase III InnovAATe clinical trial, offset by increases in sales and marketing and G&A expenses.
Net Income $4.1 million or $0.07 per diluted share in Q1 2026, up 4% compared to $4 million and $0.07 per diluted share in Q1 2025.
Adjusted EBITDA $11.6 million in Q1 2026, equivalent to GAAP reported in Q1 2025.
Cash and Cash Equivalents $73.1 million as of March 31, 2026, compared to $75.5 million as of December 31, 2025. The decrease reflects the dividend payment made in April 2026.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
KEDRAB: Continued significant increase in end-user utilization in the U.S. and growing sales in international markets such as Canada, Latin America, Australia, and Israel. Supply to Kedrion expected to exceed $90 million in sales for 2026-2027.
GLASSIA: Revenue growth driven by sales in ex-U.S. markets and royalties from Takeda in the U.S. and Canada. Efforts to expand into additional international markets are ongoing.
CYTOGAM: Initiated post-marketing research programs to demonstrate product advantages in CMV disease prevention and management. Studies indicate potential benefits in high-risk transplant recipients.
VARIZIG: Strong market demand in Latin America and the U.S. due to increased awareness and chickenpox outbreaks.
Biosimilar Products: Plans to launch two additional biosimilars in Israel by mid-2026, with a pipeline for future launches. Expected annual sales of $15-$20 million within 4-5 years.
MENA Region Expansion: Initiated distribution activities and product registration in the MENA region, with plans to expand further.
Plasma Collection Centers: FDA approval for the San Antonio plasma collection center, with plans for European Medicine Agency approval. Expected annual revenue of $8-$10 million per center at full capacity.
Operational Efficiency: Reduction in R&D expenses due to termination of Phase III InnovAATe trial, offset by increased sales and marketing investments.
Business Development and M&A: Actively evaluating opportunities to enrich the product portfolio and generate synergies with existing operations.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Temporary shipment delay: A temporary shipment delay of a single order affected the first quarter financial results, although the order was delivered in April.
Reduction in gross margin: Gross margin decreased from 47% in Q1 2025 to 42% in Q1 2026, impacted by product and market sales mix.
R&D expense reduction: Reduction in R&D expenses due to the termination of the Phase III InnovAATe clinical trial, which could impact future innovation and product development.
Regulatory approvals for plasma centers: The company is awaiting European Medicine Agency approval for its plasma collection centers, which could delay revenue generation from these facilities.
Market competition: The company faces competitive pressures in the biosimilar and specialty plasma-derived product markets, which could impact market share and profitability.
Economic uncertainties: Economic conditions and potential market fluctuations could impact demand for the company's products, particularly in international markets.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
2026 Annual Revenue and EBITDA Guidance: Kamada reiterates its 2026 annual guidance of $200 million to $205 million in revenues and $50 million to $53 million of adjusted EBITDA, representing 12% and 23% growth respectively compared to 2025 results.
Organic Growth Focus: The 2026 guidance is based solely on organic growth, with plans to expand the commercial product portfolio, including six FDA-approved specialty plasma-derived products, and grow the distribution segment through biosimilar launches in Israel and the MENA region.
Plasma Collection Expansion: Kamada plans to ramp up plasma collection at its three centers, aiming to reduce specialty plasma costs and increase revenues through sales of normal source plasma. The Houston and San Antonio facilities are expected to generate $8 million to $10 million annually at full capacity, with sales initiation planned for the second half of 2026.
Biosimilar Product Launches: Two additional biosimilars are set to launch in Israel by mid-2026, with expectations of biosimilar annual sales reaching $15 million to $20 million within 4-5 years.
CYTOGAM Utilization Growth: Kamada anticipates increased utilization of CYTOGAM, supported by ongoing post-marketing research programs and studies demonstrating its benefits in managing CMV disease.
M&A and Business Development: The company is actively pursuing M&A opportunities to enrich its product portfolio and generate synergies with its existing operations, aiming to support long-term profitable growth.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Dividend Declaration: In March, Kamada declared a dividend of $0.25 per share, totaling approximately $14.4 million. The cash dividend was paid on April 7, 2026.
Dividend Policy: Kamada has adopted a dividend policy under which it intends to distribute an annual dividend of at least 50% of its annual net income, subject to the Board's discretion and compliance with Israeli company's law.
Purpose of Dividend Payment: The dividend payment reflects confidence in the company's future business prospects and liquidity, while supporting investments in commercial growth, business development, M&A transactions, and shareholder returns.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Could you give more details on the revenue impact of the delayed shipment and which products were affected? Also, should we expect seasonality from KEDRAB and VARIZIG?
A:The delay involved a single shipment worth approximately $2.4 million, destined for an ex-U.S. territory. The delay was due to limited flights caused by the Middle East situation. KEDRAB shows some seasonality, with higher sales in summer due to increased exposure to rabid animals. VARIZIG is less seasonal, with slight increases during chickenpox outbreaks, particularly at the start of the school year.
Q:How many products are approved for sale in the distribution business?
A:Kamada distributes around 40 products in the Israeli market, representing over 20 international companies. The biosimilars segment includes three launched products, with two more expected by year-end, totaling approximately 45 products by the end of the year.
Q:Is the increase in the first quarter primarily due to the addition of three new products?
A:No, the increase was across the entire portfolio and not attributed to a single product.
Q:Will the plasma collection business start selling source plasma by the end of the year?
A:Yes, the centers have been collecting normal source plasma, and FDA approval allows sales to begin in the second half of the year. Specialty programs are also being added to the Houston and San Antonio centers.
Q:When will the Houston and San Antonio plasma collection centers reach full capacity?
A:The centers are expected to reach full capacity by late 2027 or early 2028 for normal source plasma, while specialty collections will continue to expand.
Q:What are the current trends impacting CYTOGAM?
A:Efforts are being made to expand the post-marketing clinical program. Recent studies, including one presented at the ISHLT conference, highlight CYTOGAM's relevance for high-risk transplanted patients. Investments in clinical data aim to address the lack of recent data and improve product utilization alongside antivirals.
Q:Review of Unclear Management Responses
A:None of the questions were avoided or lacked clarity. All responses were detailed and addressed the queries directly.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AAT deficiency
Agency Houston
America country
America market
Amir investor
Annual Meeting
Antonio center
Antonio facility
Argentina Russia
Assistant
CMV IVIg
Canada
Dr
FDA approval
IVIg prophylaxis
Kedrion
Latin America
MENA region
Medicine
SHIELD study
commercialization
demand product
disease opportunity
expansion distribution
immunoglobulin
lung transplant
outcome
prophylaxis risk
reminder
specialty plasma
supply
transplant recipient
KMDA Transcript
Kamada Ltd. (KMDA) Q1 2026 Earnings Call Transcript
Unknown5-13
The earnings call presents mixed signals: while there's a positive revenue growth outlook for 2026 and dividend declaration, current financials show a gross margin decline and economic uncertainties. The Q&A session didn't reveal any major concerns, but competitive pressures and regulatory delays pose risks. Without a market cap, assuming moderate impact, the overall sentiment remains neutral, balancing positive long-term guidance against short-term challenges.
Kamada Ltd. (KMDA) Q4 2025 Earnings Call Transcript
Positive3-11
The earnings call reveals strong financial performance with a 12% revenue increase and 23% EBITDA growth. The company maintains its guidance, indicating confidence in future growth. The dividend declaration and plans for biosimilar launches further support a positive outlook. While gross margins slightly declined, the overall financial health remains robust. The Q&A section addresses concerns effectively, reinforcing management's confidence. Given the positive financial metrics, strategic plans, and shareholder returns, the stock price is likely to see a positive movement in the short term.
Kamada Ltd. (KMDA) Q3 2025 Earnings Call Transcript
Positive11-10
The earnings call indicates solid financial performance with increased revenues, net income, and EBITDA. Positive guidance, ongoing product launches, and strategic initiatives like M&A and plasma expansion further bolster growth prospects. While some uncertainties exist (e.g., CMV study specifics), the overall sentiment is positive, supported by strong financials and strategic plans.
Kamada Ltd. (KMDA) Q2 2025 Earnings Call Transcript
Positive8-13
The earnings call reflects strong financial metrics, with revenue and net income growth, disciplined expense management, and a solid cash position. The company's strategic initiatives, including biosimilar launches and plasma collection expansion, are promising. While some analyst concerns about competitive landscape and vague responses on funding were noted, the overall sentiment remains positive. The reiteration of 2025 guidance and a robust product portfolio further support a positive outlook. Given the lack of market cap data, a moderate positive reaction is expected, likely resulting in a 2% to 8% stock price increase.
KMDA Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
